What is it about?
In Study 309/KEYNOTE-775, lenvatinib+pembrolizumab significantly improved progression-free survival, overall survival, and objective response rates compared with physician’s choice of single-agent doxorubicin or paclitaxel. In ENGOT-en9/LEAP-001, first-line lenvatinib+pembrolizumab demonstrated evidence of anti-tumor activity but did not meet the pre-specified statistical criteria for progression-free survival or overall survival improvement versus carboplatin+paclitaxel. We report outcomes for the sub-group of participants in these phase 3 trials who only received neoadjuvant, adjuvant, or both neoadjuvant and adjuvant platinum-based chemotherapy before enrollment in Study 309/KEYNOTE-775 or ENGOT-en9/LEAP-001.
Featured Image
Photo by Europeana on Unsplash
Why is it important?
In Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001, lenvatinib+pembrolizumab improved all measures of efficacy in this sub-group of participants, including overall survival, progression-free survival, and objective response rates. Benefits were seen regardless of mismatch repair status or platinum-free interval. The combination had a manageable safety profile.
Perspectives
Lenvatinib+pembrolizumab could be considered as an effective treatment option for this patient sub-group.
Professor David Scott Miller
University of Texas Southwestern Medical School
Read the Original
This page is a summary of: Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes, International Journal of Gynecological Cancer, July 2026, Elsevier,
DOI: 10.1016/j.ijgc.2026.104693.
You can read the full text:
Contributors
The following have contributed to this page
